0
0
Japanese pharmaceutical giant Takeda is preparing to introduce its dengue vaccine, Qdenga, in India by next year, marking a significant step in the country’s fight against the mosquito-borne disease. The launch will be executed in partnership with Hyderabad-based Biological E (Bio E), aligning with India’s ‘Make-in-India’ initiative to boost local manufacturing and accessibility.
Key Details of the Launch
-
Partnership and Production: Takeda’s collaboration with Bio E will enable large-scale production of Qdenga in India, supporting both public and private sector distribution. The vaccine will be made available through a tiered pricing model to maximize access, particularly in lower-income settings.
-
Regulatory Pathway: The regulatory approval process is currently underway, with local clinical trials being conducted to ensure safety and efficacy for the Indian population. Takeda has already submitted a comprehensive data package that supported Qdenga’s registration in 40 countries. The company anticipates licensing in India by 2026.
-
Vaccine Profile: Qdenga is a tetravalent live-attenuated vaccine, designed to protect against all four dengue virus serotypes. It follows a two-dose regimen, with doses administered three months apart. The vaccine has demonstrated efficacy in global trials and is already in use in several countries for both pediatric and adult populations.
-
Market Strategy: Takeda plans to simultaneously introduce Qdenga in both private and public sectors in India, initially focusing on pediatric immunization in line with WHO guidelines, while also making it available for adults in the private sector.
Background and Public Health Impact
Dengue remains a major health challenge in India, with hundreds of thousands of cases reported annually and significant mortality. The introduction of Qdenga is expected to bolster preventive efforts and reduce the disease burden, particularly as the vaccine targets all circulating serotypes of the dengue virus.
Disclaimer
This article is based on information available as of April 28, 2025, and details from Takeda’s official statements and public reports. The launch and availability of Qdenga in India are subject to regulatory approvals and successful completion of ongoing clinical trials. Readers are advised to consult healthcare professionals and official government sources for the most current updates regarding dengue vaccination.
Citations:
